Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05031767
Other study ID # REK no.:229187
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 7, 2021
Est. completion date January 31, 2024

Study information

Verified date February 2024
Source Diakonhjemmet Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The ReMonit study is a 18-months, non-inferiority randomized, controlled trial with three parallel arms to determine if two, new follow-up strategies for patients with axial spondyloarthritis (axSpA) are non-inferior in maintaining stable, low disease activity over time compared to the conventional follow-up regimen with regular hospital visits.


Description:

The trial will include Norwegian adult males and females with axial spondyloarthritis. 240 participants will be randomized 1:1:1 to either: 1. Control group: a. Usual care, i.e. conventional follow-up strategy with blood tests, patient-reported outcomes (PROs), and pre-scheduled visits at the hospital every 6th month 2. Remote monitoring: hospital health professionals (HPs) perform remote monitoring of frequent PROs, blood test results, and physical activity data available on a digital platform 3. Patient-initiated care: no pre-scheduled visits or remote monitoring The study has 18 months follow-up. We will use a 15% non-inferiority margin. The study will also include qualitative research including semi-structured interviews and observations of patients in the two intervention groups and health professionals involved in the study. The interviews will explore experiences with remote monitoring and video consultations.


Recruitment information / eligibility

Status Completed
Enrollment 243
Est. completion date January 31, 2024
Est. primary completion date January 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Male or non-pregnant, non-nursing female >18 years of age at screening - Patients with a diagnosis of axSpA who fulfil the diagnostic Assessment of SpondyloArthritis International Society (ASAS) criteria for axSpA - Stable medical treatment with TNFi the last 6 months - Low disease activity (ASDAS<2.1) at inclusion - Capable of understanding the Norwegian language and of signing an informed consent form Exclusion Criteria: Medical conditions: - Major co-morbidities, such as severe malignancies, severe diabetes mellitus, severe infections, uncontrollable hypertension, severe cardiovascular disease (NYHA class III or IV), severe respiratory diseases, and/or cirrhosis. - Indications of active tuberculosis (TB) Diagnostic assessments: - Abnormal renal function, defined as serum creatinine >142 µmol/L in female and >168 µmol/L in male, or glomerular filtration rate (GFR) <40 mL/min/1.73 m2 - Abnormal liver function (defined as Alanine Transaminase (ALT) >3x upper normal limit), active or recent hepatitis - Leukopenia and/or thrombocytopenia Other: - Pregnancy and/or breastfeeding (current at screening or planned within the duration of the study) - Severe psychiatric or mental disorders, alcohol abuse or other substance abuse, language barriers or other factors which makes adherence to the study protocol impossible

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Usual care
Conventional follow-up strategy with blood tests, patient-reported outcomes, and pre-scheduled visits at the hospital every 6th month. Continue using medical treatment with tumour necrosis factor inhibitors (TNFi). Patients will be instructed to use NSAIDs should they experience minor worsening of symptoms, but if the patients experience significant symptom worsening and suspect a severe disease worsening (flare) or adverse events, they will be instructed contact the hospital.
Remote monitoring
Hospital health professionals perform remote monitoring of frequent patient-reported outcomes, blood test results, and physical activity data available on a digital platform. Continue using medical treatment with tumour necrosis factor inhibitors (TNFi). Patients will be instructed to use NSAIDs should they experience minor worsening of symptoms, but if the patients experience significant symptom worsening and suspect a severe disease worsening (flare) or adverse events, they will be instructed contact the hospital .
Patient-initiated care
No pre-scheduled visits or remote monitoring. Continue using medical treatment with tumour necrosis factor inhibitors (TNFi). Patients will be instructed to use NSAIDs should they experience minor worsening of symptoms, but if the patients experience significant symptom worsening and suspect a severe disease worsening (flare) or adverse events, they will be instructed contact the hospital.

Locations

Country Name City State
Norway Diakonhjemmet Hospital Oslo

Sponsors (1)

Lead Sponsor Collaborator
Diakonhjemmet Hospital

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Primary Low disease activity at follow-up The proportion of patients with low disease activity (defined as ASDAS <2.1) at the 6-months follow-up 6 months
Primary Low disease activity at follow-up The proportion of patients with low disease activity (defined as ASDAS <2.1) at the 12- months follow-up 12 months
Primary Low disease activity at follow-up The proportion of patients with low disease activity (defined as ASDAS <2.1) at the 18-months follow-up 18 months
Secondary Ankylosing Spondylitis Disease Activity Score (ASDAS) Ankylosing Spondylitis Disease Activity Score (ASDAS) is a clinical measure of disease activity calculated from four patient-reported outcomes (PROs) and C-reactive Protein (CRP) (or erythrocyte sedimentation rate (ESR) if CRP is not available). The formula for calculating ASDAS CRP = 0.12 × back pain + 0.06 × duration of morning stiffness + 0.11 × patient global + 0.07 × peripheral pain/swelling + 0.58×Ln(CRP + 1)). Higher values indicate worse outcome. Baseline, 6, 12 and 18 months
Secondary Ankylosing Spondylitis Disease Activity Score (ASDAS) Monthly for a subgroup among the Remote monitoring group. ASDAS is a clinical measure of disease activity calculated from four PROs and CRP (or ESR if CRP is not available). The formula for calculating ASDAS CRP = 0.12 × back pain + 0.06 × duration of morning stiffness + 0.11 × patient global + 0.07 × peripheral pain/swelling + 0.58×Ln(CRP + 1)). Higher values indicate worse outcome. Every month, maximum 18 months
Secondary Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Patient-reported disease activity last 7 days on 6 items using a numeric rating scale (NRS) 0-10. The score is the sum (of the first four individual questions and the mean of questions five and six) divided by five. The sum score range 0-10; higher value indicate worse outcome. Baseline, 6, 12 and 18 months
Secondary Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Monthly reported by the Remote monitoring group if disease worsening. Patient-reported disease activity last 7 days on 6 items using a NRS 0-10. The score is the sum (of the first four individual questions and the mean of questions five and six) divided by five. The sum score range 0-10; higher value indicate worse outcome. Every month, maximum 18 months
Secondary Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Reported every third month by the Patient-initiated care group if disease worsening. Patient-reported disease activity last 7 days on 6 items using a NRS 0-10. The score is the sum (of the first four individual questions and the mean of questions five and six) divided by five. The sum score range 0-10; higher value indicate worse outcome. Baseline, 3, 6, 9, 12, 15 and 18 months
Secondary Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Reported monthly by the a subgroup among the Remote monitoring group. Patient-reported disease activity last 7 days on 6 items using a NRS 0-10. The score is the sum (of the first four individual questions and the mean of questions five and six) divided by five. The sum score range 0-10; higher value indicate worse outcome. Every month, maximum 18 months
Secondary C-Reactive Protein (CRP) CRP measured at home in a subgroup among the Remote monitoring group Every month, maximum 18 months
Secondary Patient global assessment of disease activity Patient-reported disease activity last 7 days on a NRS 0-10 ; higher value indicate worse outcome Baseline, 6, 12 and 18 months
Secondary Patient global assessment of disease activity Monthly reported by the Remote monitoring group. Patient-reported disease activity last 7 days on a NRS 0-10 ; higher value indicate worse outcome Every month, maximum 18 months
Secondary Patient global assessment of disease activity Reported every third month by the Patient-initiated care group: Patient-reported disease activity last 7 days on a NRS 0-10 ; higher value indicate worse outcome 3, 6, 9, 12, 15 and 18 months
Secondary Patient-reported flare Patient-reported experience of a significant worsening of symptoms (reflecting a flare in disease activity), response options: no, yes, uncertain. If yes or uncertain, they will be asked which date the flare occurred and the number of days it lasted. 6, 12 and 18 months
Secondary Patient-reported flare Monthly reported by the Remote monitoring group. Patient-reported experience of a significant worsening of symptoms (reflecting a flare in disease activity), response options: no, yes, uncertain. If yes or uncertain, they will be asked which date the flare occurred and the number of days it lasted. Every month, maximum 18 months
Secondary Patient-reported flare Reported every third month by the Patient-initiated care group. Patient-reported experience of a significant worsening of symptoms (reflecting a flare in disease activity), response options: no, yes, uncertain. If yes or uncertain, they will be asked which date the flare occurred and the number of days it lasted. 3, 6, 9, 12, 15 and 18 months
Secondary Bath Ankylosing Spondylitis Functional Index (BASFI) 10 item questionnaire (NRS 0-10) used to assess disease activity last 7 days. The score is the sum of each individual question divided by 10, higher value indicate worse outcome. Baseline, 6, 12 and 18 months
Secondary Activity Impairment Item no.6 from Work Productivity and Activity Impairment (WPAI): self-reported activity impairment on a NRS 0-10; higher value indicate worse outcome. Baseline, 6, 12 and 18 months
Secondary Patient-reported global change in disease activity Single item with seven-point response scale ranging from "Much worse" to "Much better". 6, 12 and 18 months
Secondary Patient-reported global change in activity impairment Single item with seven-point response scale ranging from "Much worse" to "Much better". 6, 12 and 18 months
Secondary Pain (general) Self-reported pain level last 7 days hours on a NRS 0-10; higher value indicate worse outcome. Baseline, 6, 12 and 18 months
Secondary Joint pain Self-reported joint pain level last 7 days hours on a NRS 0-10; higher value indicate worse outcome. Baseline, 6, 12 and 18 months
Secondary Sleep impairment 1 item from Pittsburgh Sleep Quality Index, self-reported sleep impairment in last month due to pain with 4 response categories ranging "Not during the past month" to "Three or more times a week" ; higher value indicate worse outcome. Baseline, 6, 12 and 18 months
Secondary Patient satisfaction with care 1 item with five point response options ranging from "Very satisfied" to "Very dissatisfied", higher value indicate better outcome Baseline, 6, 12 and 18 months
Secondary Daily steps Remote monitoring and Patient-initiated care groups, number of steps during daytime captured by wearing a smartwatch Through study completion, maximum 18 months
Secondary Mean pulse level Remote monitoring and Patient-initiated care groups, mean pulse level during daytime captured by wearing a smartwatch Through study completion, maximum 18 months
Secondary Euro Quality of Life 5 Dimensions 5 Levels (EQ5D-5L) 6 item utility instrument for measurement of health related quality of life, 5 first items with 5 response categories, item no.6: self-reported health status on a 0-100 mm scale Baseline, 6, 12 and 18 months
Secondary Concomitant medication Self-reported use of NSAIDs and analgesics and national register data from The Norwegian Prescription Register Baseline, 6, 12 and 18 months
Secondary Swollen joint count For the Control group, examiner assessed metacarpophalangeal (MCP) 1-5, proximal interphalangeal (PIP) 1-5, wrists, elbows, shoulders, ankles, forefeet Baseline, 6, 12 and 18 months
Secondary Swollen joint count At extra visits/withdrawals/early discontinuation in the Remote monitoring and Patient-initiated care groups, For the Control group, examiner assessed MCP 1-5, PIP 1-5, wrists, elbows, shoulders, ankles, forefeet Baseline, through study completion, and 18 months
Secondary Tender joint count For the Control group, examiner assessed MCP 1-5, PIP 1-5, wrists, elbows, shoulders, ankles, forefeet Baseline, 6, 12 and 18 months
Secondary Tender joint count At extra visits/withdrawals/early discontinuation in the Remote monitoring and Patient-initiated care groups, For the Control group, examiner assessed MCP1-5, PIP 1-5, wrists, elbows, shoulders, ankles, forefeet Baseline, through study completion, and 18 months
Secondary Heel enthesitis For the Control group, the presence of heel enthesitis is examined clinically by a health professional. Scored as not present/present right heel/present left heel/present both heels. Baseline, 6, 12 and 18 months
Secondary Heel enthesitis At extra visits/withdrawals/early discontinuation in the Remote monitoring and Patient-initiated care groups, , the presence of heel enthesitis is examined clinically by a health professional. Scored as not present/present right heel/present left heel/present both heels. Baseline, through study completion, and 18 months
Secondary Costs related to hospital visits Self-reported way of transport to the hospital; walking or bicycling/private car/public transportation/taxi/airplane/other. Baseline
Secondary Costs related to hospital visits Self-reported travel distance in kilometres to the hospital. Baseline
Secondary The need to take time off work for hospital visits or video consultations If in paid work, the need to take time off from work is indicated as yes or no. Baseline
Secondary Health care utilization Self-reported health care use and national register data on consultations and treatment in secondary and primary health care Baseline, 6, 12 and 18 months
Secondary Extra visits, telephone and video consultations Number of extra visits to the hospital or video consultations with a health care provider Through study completion, maximum 18 months
Secondary Withdrawals/Early discontinuation Number of withdrawals/early discontinuation Through study completion, maximum 18 months
Secondary Adverse events Number of adverse events, serious adverse events, and withdrawals because of adverse events. Through study completion, maximum 18 months
Secondary Patient-reported self-efficacy for using different digital devices, secure login and digital health services measured on a Likert scale Self-efficacy/confidence in using smartphone, tablet, computer, app's, secure login and digital health services. 6 items with Likert scale response categories: Never used, Very bad, Bad, Neither good nor bad, Good, Very good. Score range 1-5; higher scores indicate higher self-efficacy. Baseline
Secondary eHealth literacy 20 items from 4 domains of the eHealth Literacy Questionnaire (eHLQ). Four point response scale, sum domain score range 1-4. Lower scores indicate lower eHealth literacy. Baseline
Secondary Body signs and symptoms To what degree do you understand your body's signs and symptoms. Single item, 4-point Likert scale (not at all - to a large degree + do not know-option) 18 months
Secondary Patient satisfaction with remote monitoring or patient-initiated care Service User Technology Acceptability Questionnaire (SUTAQ) reported by the Remote monitoring group. 22 items in 5 subscales. Score range 1-6. Higher scores in subscales 1,2 and 5/lower scores in subscales 3 and 4 indicate higher acceptability with telehealth. 18 months
Secondary Patient satisfaction with remote monitoring or patient-initiated care Service User Technology Acceptability Questionnaire (SUTAQ) reported by the Patient-initiated care group. 3 of 22 items: #1, #10 and #11. Score range 1-6. Higher scores in indicate higher acceptability with telehealth. 18 months
Secondary Preferred follow-up strategy One item on whether the preferred follow-up strategy would be Remote monitoring or Patient-initated care reported by the two intervention groups only. 18 months
See also
  Status Clinical Trial Phase
Completed NCT05162937 - to Evaluate the Preliminary Efficacy and Safety of GR1501 Injection in Patients With Active Axial Spondyloarthritis Phase 2
Completed NCT03622658 - Efficacy and Safety of Namilumab for Moderate-to-severe Axial Spondyloarthritis Phase 2
Completed NCT03248518 - Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases N/A
Terminated NCT02437162 - A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis Phase 3
Enrolling by invitation NCT06072859 - The Impact of Simulated Forest Immersion Therapy on Pain and Anxiety in Patients Axial Spondyloarthritis (axSpA) N/A
Completed NCT02552212 - Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS Phase 3
Active, not recruiting NCT01944163 - The IMPACT of a Referral Model for Axial Spondyloarthritis in Young Patients With Chronic Low Back Pain N/A
Active, not recruiting NCT02687620 - Does Immunogenicity Have an Influence on the Efficacy of Anti-TNF Therapy in Patients With AS: An Inception Cohort Study
Completed NCT00844805 - Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1) Phase 3
Terminated NCT02897115 - A Study Treating Participants With Early Axial Spondyloarthritis (axSpA) Taking an Intense Treatment Approach Versus Routine Treatment Phase 4
Completed NCT05019547 - The Turkish Version of the Inflammatory Arthritis Facilitators and Barriers to Physical Activity
Recruiting NCT03738956 - Safety and Efficacy of Tofacitinib in the Treatment of NSAID Refractory Axial Spondyloarthritis:A Clinical Trial Phase 2/Phase 3
Enrolling by invitation NCT02962479 - Is the Human Microbiome Altered in Patients With Axial Spondyloarthritis? N/A
Completed NCT04485078 - Investigation of Central Sensitization Frequency and Related Factors in Axial Spondyloarthritis Patients
Recruiting NCT05812157 - Optimizing Anti-IL17 Antibody Therapy by Associating Fiber Supplementation to Correct Treatment-aggravated Gut Dysbiosis in Axial Spondyloarthritis - RESPOND-IL17 N/A
Completed NCT03039088 - PREDICT-SpA - French Epidemiological Study of the Evaluation of the Impact of Fibromyalgia in the TNF Alpha Treatment Effect in Axial Spondyloarthritis in Both Anti-TNF naïve and - Experienced Patients
Completed NCT04368494 - Exercise Therapy in Patients With Axial Spondyloarthritis N/A
Completed NCT03270501 - Efficacy of Golimumab in Early Axial Spondyloarthritis in Relation to Gut Inflammation Phase 3
Completed NCT03043846 - Treat to Target Trial in Axial Spondylo Arthritis : The TICOSPA (Tight Control in Spondyloarthritis)
Recruiting NCT02956824 - Incidence of MRI Sacro-Iliac Joint Anomalies in Young Women N/A